Vaxfab Enterp. (542803)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹9.95 |
| Market Cap | ₹8.53 Cr |
| P/E Ratio | 153.35 |
| ROCE | 0% |
| ROE | 2.94% |
| Dividend Yield | 0% |
| Profit Growth | -150.55% |
| Debt/Equity | — |
| Sales Growth | -65.79% |
| 52-Week Range | ₹29.05 — ₹55.99 |
| Sector | Commercial Services & Supplies |
| Book Value | ₹3.92 |
Strengths
- The stock has already fallen roughly 82% from its 52-week high of ₹55.99, removing some speculative froth.
- Latest quarter sales of ₹16 Cr far exceed the ₹9 Cr market cap, implying a low price-to-sales ratio on run-rate activity.
- A small ₹9 Cr market cap could offer high operating leverage if management ever stabilises the business.
- Book value per share of ₹3.92 provides some asset support, though the price is still 2.54 times book.
Concerns
- Latest quarter net loss of ₹3 Cr on ₹16 Cr sales shows severe cash burn.
- Sales growth of -65.79% and profit growth of -150.55% indicate collapsing demand and earnings.
- ROCE of 0.00% and ROE of 2.94% show capital is earning no meaningful return.
- Piotroski F-score of 2/9 and undisclosed promoter holding raise governance and financial-health red flags.
AI Analysis
Vaxfab Enterp is precisely the kind of business I would normally walk away from. A trading and distribution company rarely has a durable moat, and the numbers confirm my suspicion. The latest quarter shows ₹16 Cr of sales and a ₹3 Cr net loss—that is roughly an 18% negative margin. Sales growth is minus 65.79%, profit growth is minus 150.55%, and ROCE is a flat 0.00%. This is not a temporary pothole; it is a business losing altitude quickly. A Piotroski F-score of 2 out of 9 tells me the financial health is poor, and promoter holding is not even disclosed, which makes me uncomfortable. At ₹9.95, the stock trades at 2.54 times book value of ₹3.92 and a reported P/E of 153.35. That P/E is meaningless when the most recent quarter is loss-making. Graham would say there is no margin of safety here. The only positive is the tiny ₹9 Cr market cap relative to the quarterly sales run-rate, so a genuine turnaround could produce explosive percentage returns. But that is speculation, not investment. I need evidence: sales stabilisation, narrowing losses, positive operating cash flow, and an F-score moving above 5. Until then, this belongs on the too-hard pile.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer